Latest On Bioanalytical Systems, Inc (BASI):
| Date/Time | Type | Description | Signal | Details |
|---|---|---|---|---|
| 2022-01-18 17:52 EST | News | Basis Global Technologies Starts U.S. IPO Effort | N/A |  |
| 2021-03-20 12:23 EST | News | Bioanalytical Systems announces name change to Inotiv (NOTV) | N/A | |
| 2021-03-18 12:11 EST | Analyst Rating | The Analyst Target Price has increased from $21 to $23. | Buy | |
| 2021-03-17 19:11 EST | News | Bioanalytical Systems to expand service offerings | N/A | |
| 2021-02-12 07:12 EST | Analyst Rating | The Analyst Target Price has increased from $17 to $21. | Buy | |
About Bioanalytical Systems, Inc (BASI):
Bioanalytical Systems, Inc., doing business as Inotiv, provides drug discovery and development services to the pharmaceutical, chemical, and medical device industries; and sells analytical instruments to the pharmaceutical development and contract research industries. It operates through two segments, Contract Research Services and Research Products. The Contract Research Services segment offers screening and pharmacological testing, nonclinical safety testing, formulation development, regulatory compliance, and quality control testing services. This segment provides analytical method development and validation; drug metabolism, bioanalysis, and pharmacokinetics testing to identify and measure drug and metabolite concentrations in complex biological matrices; in vivo sampling services for read more...the continuous monitoring of chemical changes in life; stability testing to ensure the integrity of various solutions used in nonclinical and clinical studies, and post-study analyses; non-clinical toxicology and pathology services; and climate-controlled archiving services for its customers' data and samples. The Research Products segment designs, develops, manufactures, and markets in vivo sampling systems and accessories, including disposables, training, and systems qualification; physiology monitoring tools; liquid chromatography and electrochemistry instruments platforms; analytical products comprising liquid chromatographic and electrochemical instruments with associated accessories; and in vivo sampling products consisting of Culex family of automated in vivo sampling and dosing instruments. The company operates in the United States, rest of North America, the Pacific Rim, Europe, and internationally. Bioanalytical Systems, Inc. was founded in 1974 and is headquartered in West Lafayette, Indiana.
General
- Name Bioanalytical Systems, Inc
- Symbol BASI
- Type Common Stock
- Exchange NASDAQ
- Currency USD
- Country USA
- SectorHealthcare
- IndustryDiagnostics & Research
- Full Time Employees 397
- Fiscal Year EndSeptember
- IPO Date1997-11-24
- Gic SectorHealth Care
- Gic GroupPharmaceuticals, Biotechnology & Life Sciences
- Gic IndustryLife Sciences Tools & Services
- Gic SubIndustryLife Sciences Tools & Services
- Web URLhttp://www.basinc.com
Valuation
- Price/Sales (Trailing 12 Mt.) 2.38
- Price/Book (Most Recent Quarter) 21.35
- Enterprise Value Revenue 2.96
- Enterprise Value EBITDA 86.2
Financials
- Most Recent Quarter 2020-12-31
- Current Year EPS Estimate -$0.21
- Next Year EPS Estimate $0.09
- Next Quarter EPS Estimate -$0.08
- Profit Margin -6%
- Operating Margin -1%
- Return on Assets -1%
- Return on Equity -41%
- Revenue 65.44 million
- Earnings Per Share -$0.12
- Revenue Per Share $5.98
- Gross Profit 18.24 million
- Quarterly Earnings Growth 38.5%
Highlights
- Market Capitalization 167.19 million
- EBITDA 3.35 million
- Analyst Target Price $23
- Book Value Per Share $0.67
Share Statistics
- Shares Outstanding 11.13 million
- Shares Float 5.92 million
- % Held by Insiders 3492%
- % Held by Institutions 10.67%
- Shares Short 57445
- Shares Short Prior Month 53484
- Short Ratio 0.53
- Short % of Float 1%
- Short % of Shares Outstanding 1%
Technicals
- Beta 2
- 52 Week High $21.08
- 52 Week Low $3.05
- 50 Day Moving Average 15.53
- 200 Day Moving Average 9.43
Dividends
- Dividend Date N/A
- ExDividend Date N/A
- Dividend Yield 0%
Bioanalytical Systems, Inc (BASI) Dividend Calendar:
Bioanalytical Systems, Inc (BASI) Earnings History:
Companies typically report earnings on both a quarterly and annual basis. Earnings reported that deviate from analysts' expectations can have a large impact on a stock's price.
Bioanalytical Systems, Inc (BASI) Company Financial Statements:
Financial statements are reports prepared by a company's management to present their financial performance and position at a point in time. A general-purpose set of financial statements usually includes a balance sheet, income statements, and statement of cash flows.
Income Statement:
| Date |
|---|
| Research Development |
| Income Before Tax |
| Selling General Administrative |
| Gross Profit |
| Ebit |
| Operating Income |
| Income Tax Expense |
| Total Revenue |
| Cost of Revenue |
| Total Other Income Expense Net |
| Net Income From Continuing Operations |
| Net Income Applicable to Common Shares |
Cash Flow:
| Date |
|---|
| Investments |
| Change to Liabilities |
| Total Cash Flow from Investing Activities |
| Net Borrowings |
| Total Cash Flow from Financial Activities |
| Change to Operating Activities |
| Change in Cash |
| Total Cash from Operating Activities |
| Depreciation |
| Other Cash Flow from Investing Activities |
| Change to Inventory |
| Change to Account Receivables |
| Other Cash Flow from Financing Activities |
| Change to Net Income |
| Capital Expenditures |
Balance Sheet:
| Date |
|---|
| Total Liabailities |
| Total Stockholder Equity |
| Other Current Liabilities |
| Total Assets |
| Common Stock |
| Other Current Assets |
| Retained Earnings |
| Other Liabilities |
| Other Assets |
| Cash |
| Total Current Liabilities |
| Other Stockholder Equity |
| Property, Plant & Equipment |
| Total Current Assets |
| Long Term Investments |
| Net Tangible Assets |
| Short Term Investments |
| Long Term Debt |
| Inventory |
| Accounts Payable |
Bioanalytical Systems, Inc (BASI) Chart:
Bioanalytical Systems, Inc (BASI) News:
Below you will find a list of latest news for Bioanalytical Systems, Inc (BASI) from major news sources. You can filter the results to only show news from a specific source.
No recent news available
Bioanalytical Systems, Inc (BASI) Options:
A stock option is a contract between two parties in which the stock option buyer (holder) purchases the right (but not the obligation) to buy/sell 100 shares of an underlying stock at a predetermined price from/to the option seller (writer) within a fixed period of time.
Bioanalytical Systems, Inc (BASI) SEC Filings:
An SEC filing is a financial statement or other formal document submitted to the U.S. Securities and Exchange Commission (SEC). Public companies, certain insiders, and broker-dealers are required to make regular SEC filings.
| Date | Form Type | View |
|---|---|---|
| 2020-09-18 | 8-K (Current report) | |
| 2020-09-16 | 8-K (Current report) | |
| 2020-08-20 | 4 (Statement of changes in beneficial ownership of securities) | |
| 2020-08-19 | 4 (Statement of changes in beneficial ownership of securities) | |
| 2020-08-14 | 10-Q (Quarterly report [Sections 13 or 15(d)]) | |
| 2020-06-17 | 8-K (Current report) | |
| 2020-06-17 | 8-K (Current report) | |
| 2020-06-16 | 4 (Statement of changes in beneficial ownership of securities) | |
| 2020-06-11 | 4 (Statement of changes in beneficial ownership of securities) | |
| 2020-05-22 | 4 (Statement of changes in beneficial ownership of securities) | |
| 2020-05-21 | 4 (Statement of changes in beneficial ownership of securities) | |
| 2020-05-15 | 8-K (Current report) | |
| 2020-05-14 | 10-Q (Quarterly report [Sections 13 or 15(d)]) | |
| 2020-04-24 | 8-K (Current report) | |
| 2020-04-06 | S-8 (Securities to be offered to employees in employee benefit plans) | |
| 2020-04-03 | 4 (Statement of changes in beneficial ownership of securities) | |
| 2020-04-03 | 4 (Statement of changes in beneficial ownership of securities) | |
| 2020-04-03 | 4 (Statement of changes in beneficial ownership of securities) | |
| 2020-03-31 | 8-K (Current report) | |
| 2020-03-20 | 8-K (Current report) | |
Bioanalytical Systems, Inc (BASI) Insider Transactions:
Here you will find a list of insider trading activities (stock purchases, sales, and option exercises) reported by insiders of Bioanalytical Systems, Inc (BASI). Company insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise.
Insider Ownership: 3492%
Institutional Ownership: 1067%
| Transaction Date | Insider Name | Insider Title | Type | Shares Number | Shares Price | Total Transaction | Shares Held After Transaction | Link |
|---|---|---|---|---|---|---|---|---|
| 2020-08-19 | R Matthew Neff | Director | Buy | 5,000.00 | 4.75 | 23,750.00 | 60,350.00 | |
| 2020-08-19 | John E Sagartz | Chief Strategy Officer | Buy | 3,733.00 | 4.75 | 17,731.75 | 634,232.00 | |
| 2020-06-15 | Robert Jr. Leasure | President and CEO | Buy | 2,884.00 | 5.20 | 14,996.80 | 186,549.00 | |
| 2020-06-10 | Beth Taylor | VP- Finance & CFO | Buy | 10,000.00 | 23,300.00 | | ||
| 2020-05-21 | Beth Taylor | VP- Finance & CFO | Buy | 3,300.00 | 4.52 | 14,916.00 | 13,300.00 | |
| 2020-05-21 | William D Pitchford | Chief HR Officer | Buy | 10,000.00 | 4.47 | 44,700.00 | 32,000.00 | |
| 2020-05-20 | Beth Taylor | VP- Finance & CFO | Buy | 4,933.00 | 4.42 | 21,803.86 | 10,000.00 | |
| 2020-05-19 | Beth Taylor | VP- Finance & CFO | Buy | 5,067.00 | 4.38 | 22,193.46 | 5,067.00 | |
| 2020-04-01 | Gregory Cole Davis | Director | Buy | 10,000.00 | 30,000.00 | | ||
| 2020-04-01 | Richard Allen Johnson | Director | Buy | 10,000.00 | 40,000.00 | | ||
| 2020-04-01 | R Matthew Neff | Director | Buy | 10,000.00 | 55,350.00 | | ||
| 2020-03-16 | Robert Jr. Leasure | President and CEO | Buy | 5,700.00 | 3.49 | 19,893.00 | 183,665.00 | |
| 2020-03-13 | R Matthew Neff | Director | Buy | 3,350.00 | 3.93 | 13,165.50 | 45,350.00 | |
| 2020-03-12 | R Matthew Neff | Director | Buy | 12,000.00 | 3.80 | 45,600.00 | 42,000.00 | |
| 2020-02-20 | R Matthew Neff | Director | Buy | 9,458.00 | 4.60 | 43,506.80 | 30,000.00 | |
| 2020-02-20 | Richard Allen Johnson | Director | Buy | 20,000.00 | 4.63 | 92,600.00 | 30,000.00 | |
| 2020-01-27 | Robert Jr. Leasure | President and CEO | Buy | 13,000.00 | 177,965.00 | | ||
| 2019-12-02 | Joseph Earl Flynn | Chief Commercial Officer | Buy | 2,564.00 | 127,514.00 | | ||
| 2019-12-02 | Michael Baim | VP Bioanalytical Services | Buy | 7,718.00 | 22,718.00 | | ||
| 2019-12-02 | Philip A Downing | Sr. VP, Preclinical Srvcs. | Buy | 8,436.00 | 34,201.00 | |